EADV: European Academy of Dermatology and Venereology

These 28-week data on twice-daily ESK-001 highlight the drug’s safety and efficacy among patients with psoriasis.

SUNSHINE and SUNRISE trial data will be submitted to the FDA as part of Novartis’ Biologics License Application (BLA) for secukinumab in hidradenitis suppurativa.

The 4-part lecture, “Practical Application of Novel Targeted Strategies in Moderate-to-Severe Atopic Dermatitis” covered the pathogenesis of atopic dermatitis (AD), new insights into the pathophysiology in AD, considerations for change in the treatment of AD, and the latest developments in treatment.

Positive data from two Phase 3 clinical trials that show Dupixent (dupilumab) is effective in the treatment of moderate-to-severe atopic dermatitis was announced at the 25th European Academy of Dermatology and Venereology Congress in Vienna, Austria.

Demonstrating the efficacy of antiretroviral therapies and other treatments in preventing the spread of HIV, Thomas Quinn, MD, showed that there is hope for decreasing HIV transmissions across the world. He cautioned, however, that HIV/AIDS still remains a global pandemic, and more work must be done to accelerate the rate of decrease in HIV infections.

For a long time, researchers were unsure if atopic dermatitis was primarily a barrier disease or an immune-driven disease, but dupilumab has provided a more clear-cut answer, said Emma Guttman-Yassky, MD, PhD, of the Icahn School of Medicine at Mount Sinai Medical Center in New York.

Timothy M. Johnson, MD, spoke enthusiastically about the possibilities of sentinel lymph node biopsy in his lecture at the 25th European Academy of Dermatology and Venereology Congress in Vienna, Austria. His presentation, called “Melanoma Sentinel Node Biopsy: Past, Present and Future in the New Era of Systemic Therapies,” covered guidelines for the procedure as well as new possibilities for melanoma patients.

Thursday at the 25th European Academy of Dermatology and Venereology Congress in Vienna, Austria, 2 presentations focused on the effects of crisaborole topical ointment, 2%, in treating atopic dermatitis.

Patients with melanoma have more promising options than ever with the advent of targeted therapies and immunotherapies, said Mario Lacouture, MD, director of the Oncodermatology Program at Memorial Sloan Kettering Cancer Center. His research aims to provide patients the best possible quality of life while taking these treatments, which can often have adverse effects.

Research has shown that care provided through teledermatology is comparable to that delivered in face-to-face appointments, and future dermatologists are being taught to deliver care this way to improve patient access to expert dermatological care, said Nellie Konnikov, MD, professor and chief of dermatology at the Boston Department of Veterans Affairs.

Focus on behavioral interventions to prevent HIV transmission has been unsuccessful but the more recent intervention of using antiretroviral drugs has more promise, said Thomas C. Quinn, MD, director of the Johns Hopkins Center for Global Health.

A recent clinical trial found that SD-101, a new proprietary topical allantoin cream, can help treat epidermolysis bullosa (EB). The study is a breakthrough in EB treatment and research as treatment options for this rare and painful rare connective tissue disorder are limited.

Mohs surgery is generally the gold standard for rare and more aggressive tumors because the surgeon can ensure the roots of the tumor are gone, but the technique keeps the hole small, said Ally-Khan B. Somani, MD, PhD, at the 25th European Academy of Dermatology and Venereology Congress.

Plenary lecturer Stephen I. Katz, MD, PhD, director of the National Institute of Arthritis and Musculoskeletal and Skin Diseases, and adjunct investigator in the Dermatology Branch of the National Cancer Institute opened the 25th European Academy of Dermatology and Venereology Congress in Vienna, Austria, with a discussion on past and future advances in dermatology.

Reimbursement issues surrounding Mohs surgery are getting worse, which provides a challenge for surgeons who would perform the procedure, explained Aleksandar L. Krunic, MD, PhD, during the 25th European Academy of Dermatology and Venereology Congress.